鹭燕医药（002788）新增【人脑工程】概念

Core Insights - The article highlights that Luyan Pharmaceutical (002788) has added the "Brain Engineering" concept due to its transaction records with the distributor of Borui Kang, which is the first company in China to complete clinical trials for minimally invasive brain-machine interfaces [1] Company Overview - Luyan Pharmaceutical's main business includes the distribution of pharmaceuticals, traditional Chinese medicine pieces, medical devices, and vaccines, as well as retail pharmacy chains [1] Financial Performance - For the first three quarters of 2025, Luyan Pharmaceutical reported a main revenue of 15.855 billion yuan, an increase of 2.87% year-on-year [1] - The net profit attributable to shareholders was 220 million yuan, a decrease of 14.64% year-on-year [1] - The net profit after deducting non-recurring items was also 220 million yuan, down 15.14% year-on-year [1] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 5.455 billion yuan, up 6.81% year-on-year [1] - The single-quarter net profit attributable to shareholders was 65.1366 million yuan, a decline of 2.74% year-on-year [1] - The single-quarter net profit after deducting non-recurring items was 66.6689 million yuan, down 7.93% year-on-year [1] - The company's debt ratio stands at 74.98%, with investment income reported at -10.8849 million yuan and financial expenses at 139 million yuan, while the gross profit margin is 6.96% [1]